What is Upper Airway Cough Syndrome (UACS) and its appropriate management for an elderly female with stage 4 chronic kidney disease, hypertension, anemia, macular degeneration, and a recent viral‑like illness presenting with a persistent non‑productive cough?

What is Upper Airway Cough Syndrome?

Upper Airway Cough Syndrome (UACS) is a clinical syndrome in which chronic cough results from mechanical or inflammatory stimulation of cough receptors in the hypopharynx and larynx by secretions draining from the nose and sinuses, and it is the single most common cause of chronic cough in adults. 1

Definition and Terminology

• The American College of Chest Physicians officially recommends using the term "Upper Airway Cough Syndrome" instead of the older term "postnasal drip syndrome" because UACS more accurately describes the pathophysiology of chronic cough related to upper airway abnormalities. 1

• UACS is a clinical diagnosis that cannot be confirmed by any objective test—there is no way to quantify postnasal drip or directly prove it causes cough. 1

• The diagnosis relies on a combination of symptoms, physical examination findings, and most critically, improvement or resolution of cough in response to specific therapy is the pivotal factor confirming the diagnosis. 1

Epidemiology and Prevalence

• UACS is the most common cause of both acute and chronic cough in adults, accounting for 18.6%–81.8% of chronic cough cases either alone or in combination with other conditions. 1, 2

• In nonsmokers with normal chest radiographs who are not taking ACE inhibitors, UACS, asthma, and gastroesophageal reflux disease together account for approximately 90% of chronic cough cases. 2, 3, 4

• Approximately 20% of patients with UACS are completely unaware of postnasal drainage or its connection to their cough—this "silent" presentation makes the diagnosis challenging but does not exclude it. 1, 2

Pathophysiology

• The primary mechanism is mechanical stimulation of cough receptors located in the hypopharynx or larynx by secretions draining from the nose and/or sinuses. 1

• Evidence suggests that patients with UACS have increased sensitivity of the cough reflex in the upper airway compared to normal individuals, contributing to symptom severity. 1

• Alternative mechanisms include chemical irritation of the afferent limb of the cough reflex and possible aspiration of secretions stimulating lower respiratory tract receptors, though data supporting these mechanisms are limited. 1

Clinical Presentation

Common Symptoms

• Sensation of something draining into the throat (though absent in 20% of cases) 1

• Frequent throat clearing 1, 2

• Nasal discharge or congestion 1, 2

• Tickle sensation in the throat 1

• Recent upper respiratory infection (common historical feature) 1

• Cough that worsens when lying down (due to gravity-driven drainage) 2

Physical Examination Findings

• Cobblestone appearance of the oropharyngeal mucosa (relatively sensitive but not specific) 1, 2

• Visible mucoid or mucopurulent secretions in the posterior pharynx or oropharynx 1, 2

• These findings are present in many patients with cough from other causes, so they cannot definitively establish the diagnosis. 1

Critical Diagnostic Pitfall

• Cough characteristics (productive vs. non-productive, timing, quality) are completely unreliable for diagnosing UACS and should NOT be used to rule in or rule out the condition. 2, 3

Underlying Etiologies

• Allergic rhinitis (~28% of UACS cases): seasonal or perennial symptoms, sneezing, nasal itching, clear rhinorrhea 2, 3

• Vasomotor rhinitis and non-allergic rhinitis (~22% of cases): sudden profuse watery discharge triggered by temperature changes, odors, or irritants 2

• Chronic sinusitis (~31% of cases): may produce relatively non-productive cough and can be "clinically silent" without typical acute sinusitis signs 2, 3

• Post-infectious rhinitis: follows upper respiratory infection 2

• Anatomic abnormalities: deviated septum, adenoid tissue (~16% of cases), polyps 2

Management Approach for Your Patient

Initial Empiric Therapy (Diagnostic and Therapeutic)

Start immediately with a first-generation antihistamine/decongestant combination as first-line therapy. 1, 2, 3

• Recommended regimens include:

  • Dexbrompheniramine 6 mg + pseudoephedrine 120 mg (sustained-release) twice daily 2, 3
  • Chlorpheniramine 4 mg four times daily 2
  • Brompheniramine 12 mg twice daily 2

• Second-generation antihistamines (loratadine, fexofenadine, cetirizine) are completely ineffective for UACS because they lack anticholinergic activity. 2, 3, 5

• First-generation antihistamines work primarily through anticholinergic properties that reduce secretions, not through antihistamine effects. 2, 3, 5

Special Considerations for Your Elderly Patient with CKD and Hypertension

• Monitor blood pressure closely after initiating decongestant therapy, as pseudoephedrine can worsen hypertension and cause tachycardia. 3

• To minimize sedation from first-generation antihistamines, start with once-daily dosing at bedtime for a few days before increasing to twice-daily therapy. 3

• Common side effects include dry mouth and transient dizziness; more serious effects include urinary retention, insomnia, jitteriness, and increased intraocular pressure in glaucoma patients. 3

• If decongestants are contraindicated due to uncontrolled hypertension, consider ipratropium bromide nasal spray (42 mcg per spray, 2 sprays per nostril 4 times daily) as an alternative that provides anticholinergic drying without systemic cardiovascular effects. 3

Timeline and Response Assessment

• Most patients improve within days to 2 weeks of initiating therapy. 3

• If no response after 2 weeks of adequate antihistamine/decongestant therapy, proceed to sinus imaging (CT scan). 2, 3

• Complete resolution may take several weeks to a few months. 3

Escalation Strategy

If inadequate response after 1–2 weeks, add intranasal corticosteroids:

• Fluticasone propionate 100–200 mcg daily (1–2 sprays per nostril) for a 1-month trial 2, 3

• Intranasal corticosteroids are the most effective monotherapy for both allergic and non-allergic rhinitis and work synergistically with antihistamines. 3

Adjunctive Therapy

• High-volume saline nasal irrigation (150 mL) mechanically removes secretions, improves mucociliary function, and reduces inflammatory mediators—more effective than saline spray. 3

Evaluation for Coexisting Conditions

If cough persists despite 2 weeks of adequate upper airway treatment, sequentially evaluate for:

1. Asthma/cough-variant asthma: Consider bronchoprovocation testing or empiric trial of inhaled corticosteroids 2, 3

2. Gastroesophageal reflux disease (GERD): Initiate omeprazole 20–40 mg twice daily before meals for at least 8 weeks plus dietary modifications (improvement may take up to 3 months) 2, 3

3. Chronic sinusitis: Obtain sinus CT if purulent discharge, facial pain, or persistent symptoms despite topical therapy 2, 3

• Multiple conditions frequently coexist—maintain all partially effective treatments rather than discontinuing them prematurely. 3

Common Pitfalls to Avoid

• Do not assume absence of upper airway symptoms excludes UACS—20% of patients have "silent" postnasal drip. 1, 2

• Do not rely on cough characteristics (productive vs. non-productive, timing) to differentiate UACS from other causes. 2

• Do not use second-generation antihistamines for diagnosis or treatment of UACS. 2, 3

• Do not prescribe antibiotics during the first week of symptoms, even with purulent nasal discharge or sinus imaging abnormalities, as these findings cannot distinguish viral from bacterial sinusitis. 3

• Do not use topical nasal decongestants (oxymetazoline, xylometazoline) for more than 3–5 consecutive days due to risk of rhinitis medicamentosa (rebound congestion). 3

• Do not evaluate UACS in isolation—always assess for possible coexisting asthma or GERD, especially when response to therapy is partial. 2, 3